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Abstract
This study was aimed to investigate the urine kinetics of isoflavones after oral intake of soymilk in healthy adults in Taiwan. Nine
volunteers received 800 mL of soymilk equivalent to 200 g of soybeans and the urine were collected from 0 to 48 h. Daidzein, equol and
genistein in urine were assayed by HPLC before and after hydrolysis with β-glucuronidase and sulfatase. The results revealed that the
parent forms of daidzein and genistein were not detected in the urine with major forms being the glucuronides (G) and sulfates (S), mainly
G. Besides, equol G and S, the metabolites of daidzein, were detected in the urine of all subjects. In conclusion, G and S of daidzein and
genistein, mainly G, were excreted in the urine of healthy adults in Taiwan after ingestion of soymilk. In addition, G and S of equol were
found in urine of all nine subjects.
Key words: soymilk, isoflavone, urine kinetics

Introduction
Dietary flavonoids, a class of semi-essential food components(1), have long been thought to exert protective effects
against many diseases, in particular cardiovascular disease
and even cancer(2). Soybean, an essential part of Asian diet, is
a rich source of isoflavones, a subfamily of flavonoids. There
are many epidemiological reports describing the health
effects of soy-rich food on the prevention of estrogen-related
cancers, cardiovascular diseases and osteoporosis(3). Due to
the adverse effect of hormone replacement therapy (HRT),
isoflavone supplements are becoming popular alternatives
for HRT(4).
Soymilk at breakfast has long been a habit for many
Chinese people. The popularity of soymilk has also spread
to the West as a substitute for cow milk. Soymilk contains
several isoflavones including daidzin, genistin, daidzein and
genistein, all of which are possibly beneficial to health(3,4).
The in vitro activities of soy isoflavones have been shown
to include chemoprevention(5-7), antioxidation(8-10)and
estrogenic effect(11,12). In addition, isoflavone metabolites
were found to be weakly estrogenic and capable of activating human natural killer cells(13,14). Furthermore, recent
in vivo studies have found that soy isoflavones increase the
bone mass in osteoporotic mice(15), and suppress the growth
* Author for correspondence. Tel: +886-4-22031028;
E-mail: pdlchao@gmail.com

of colon tumors in rats(16), as well as improve aging and
Alzheimer’s disease in mice(17).
The absorption of daidazin and genistin through
intestine is limited because of its poor lipophilicity, while
cleavage of the sugar moiety by enteral microflora converted
them into more lipophilic aglycones which are absorbable by
the intestine. Moreover, the aglycones daidzein and gensitein
were then subject to further metabolism(18,19). Despite many
studies reporting the metabolism and bioavailability of soy
isoflavones in adults after intake of soy products(12,20-22),
there is limited information concerning isoflavone pharmacokinetics of soymilk in Chinese subjects(23,24). This study
investigated the urine kinetics of isoflavones in healthy
adults in Taiwan given soymilk.

Materials and Methods
I. Subjects
Nine healthy volunteers (6 males and 3 females), 22 - 57
years old and weighing 52 - 72 kg, provided their informed
consents. Routine biochemical tests indicated that their
hepatic and renal functions were in good condition. In this
study, all of the subjects took regular diets including soy
products once a while. Only one of them was habitual drinker
of soymilk. They did not smoke or drink alcoholic beverages
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and have not taken soy products for at least 2 weeks before and
throughout the experiment. The present study was conducted
according to the guidelines in the Declaration of Helsinki,
and all protocols involving human subjects were approved by
the Medical Ethics Committee of China Medical University.
II. Chemicals
Daidzin (purity 98%), daidzein (purity 98%), equol
(purity 99%), genistin (purity 98%), genistein (purity 98%),
ethylparaben (purity 99%), 5,7-dimethoxycoumarin (purity
98%), sulfatase (Type H-1, 14,400 units/g, from Helix
pomatia, containing 574,000 unit/g of β-glucuronidase) and
β-glucuronidase (type B-1, 666,400 units/g, from bovine
liver) were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). L(+)-Ascorbic acid was obtained from RdH
Laborchemikalien GmbH & Co. KG (Seelze, Germany).
Milli-Q plus water (Millipore, Bedford, MA, USA) was used
for all preparations. Acetonitrile, methanol and ethyl acetate
were of LC grade and purchased from Mallinckrodt Baker,
Inc. (Phillipsburg, NJ, USA). Other reagents were of HPLC
grade or analytical reagent grade.
III. Instrumentation
An HPLC apparatus (Shimadzu LC-10AT, Japan) was
equipped with an autoinjector (SIL-10A) and a photodiode
array detector (SPD-M 10AVP). The column used is a
Cosmosil C18 (5 μm, 250 × 4.6 mm) with a guard column
(MetaGuard 4.6 mm Polaris 5 μm C18-A, MetaChem,
Torrance, USA).
IV. Preparation of Soymilk and Quantitation of Isoflavones
Soybeans (3 kg) were macerated in water for 12 h and
then homogenized with 12 L water by using a food processor.
The homogenate was filtered with cloth, and the filtrate
was heated with stirring for 30 min and kept simmering for
10 min; then sufficient hot water was added to make 12 L.
Soymilk (3.0 mL) was mixed with 7 mL of 60% acetonitrile
and centrifuged, the residue was extracted again with 10 mL
of 60% acetonitrile with ultrasonic shaking for 30 min(25).
The extracts were combined and 60% acetonitrile was added
to make 20 mL and then frozen at -30°C pending analysis.
The mobile phase of HPLC comprised 0.1% phosphoric acid
(A) and acetonitrile (B) with gradient program as follows:
A/B : 89/11 (0 min), 82/18 (10 min), 50/50 (20 min), 89/11
(35 min). The UV detector was set at 250 nm and the flow rate
was 1.0 mL/min.
Daidzin, daidzein, genistin and genistein were accurately weighed and dissolved in methanol to afford a series
of standards in the concentration range of 7.8 - 100.0 μg/mL.
An equal volume of internal standard solution (5,7-dimethoxycoumarin in methanol, 100.0 μg/mL) was added to
each standard to afford a final concentration of 50.0 μg/mL.
Calibration curves were plotted by linear regression of the
peak - area ratios (daidzin, daidzein, genistin and genistein

to internal standard) against concentrations of correspondent
isoflavone.
The precision and accuracy of the assay method were
evaluated by intra-day and inter-day analysis of triplicate
standards in methanol at 7.8 - 100.0 μg/mL within one day
and over a period of three consecutive days. A recovery study
was carried out by spiking appropriate amounts of daidzin,
daidzein, genistin and genistein into soymilk, which has
been quantitatively analyzed in triplicates to afford additional concentrations of 50, 25 and 6.25 µg/mL, respectively.
V. Soymilk Ingestion and Urine Collection
After overnight fasting, each volunteer ingested 800 mL
of warm soymilk (equivalent to 200 g of soybeans) within 30
min. Food was withheld for another 3 h. Urine samples were
collected before and over 0 - 2, 2 - 4, 4 - 6, 6 - 8, 8 - 10, 10 - 12,
12 - 24, 24 - 36 and 36 - 48 h period after intake of soymilk. In
each collection time interval, the volume of pooled urine was
recorded and 20 mL of homogeneous aliquots were stored at
-30°C before analysis.
VI. Quantitation of the Parent Forms and Isoflavone
Metabolites
The parent forms and conjugated metabolites of isoflavones in urine were determined before and after treatments
with β-glucuronidase and sulfatase. For the quantitation
of glucuronides (G), 400 µL urine was added with 100 µL
β-glucuronidase (1,000 units/mL) in acetate buffer, pH 5, and
100 µL ascorbic acid (200 mg/mL), and incubated at 37°C
for 4 h. For the quantitation of sulfates/ glucuronides (S/G),
100 µL sulfatase (1,000 units/mL containing 39,861 unit/mL
β-glucuronidase) and 100 µL ascorbic acid (200 mg/mL)
were added to 400 µL urine and incubated at 37°C for 2 h.
After hydrolysis, 600 µL of the mixture was partitioned with
600 µL of ethyl acetate (containing 5.0 µg/mL of ethyl
paraben as internal standard). The ethyl acetate layer was
evaporated under nitrogen to dryness and resolubilized with
50 µL of mobile phase which comprised 0.1% phosphoric
acid (A), acetonitrile (B) and methanol (C) with A : B : C =
64 : 26 : 10.
For calibrator preparations, blank urine was spiked
with various standard solutions of daidzein, equol and
genistein to afford urine standards in concentration range of
0.6 - 20.0 µg/mL. The pretreatment of urine standards and
HPLC condition were identical with those described above
for urine samples except the addition of enzyme, which was
substituted with equal volume of pH 5.5 buffer. The calibration curves for urine were plotted by linear regressions of the
peak area ratios of daidzein, equol and genistein to internal
standard against concentrations of each isoflavone.
VII. Validation of Assay Method for Urine
The precision and accuracy of the analytical method
was evaluated by intra-day and inter-day analysis of
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Daidzin, genistin, daidzein and genistein in soybean
milk as well as the internal standard were well resolved within
35 min as shown in Figure 1. Good linearity were shown in
the range of 7.8 to 100.0 µg/mL for daidzin, genistin, daidzein

and genistein. Validation of this assay method indicated that
all coefficients of variation for intraday and interday analysis
were below 5.0%, and the relative errors were below 8.6%.
The recoveries of daidzin, genistin, daidzein and genistein
from soymilk were 89.1 - 97.2%, 89.1 - 90.4%, 87.0 - 94.2%
and 81.9 - 87.1%, respectively. Quantitation results indicated
that 800 mL of soymilk contained daidzin 96.9 mol (40.3 mg),
daidzein 65.1 mol (16.6 mg), genistin 254.0 mol (109.7 mg)
and genistein 58.4 mol (15.8 mg).
The chromatograms of urine extract before and after
enzymolysis were shown in Figure 2. Good linearities of
daidzein, equol and genistein in the range of 0.6 - 20.0 μg/mL.
All coefficients of variation for intraday and interday analysis
were less than 9.3%, and the relative errors were below 9.6%.
The recoveries of daidzein, equol and genistein from urine
were 94.3 - 100.5%, 94.7 - 95.4% and 94.3 - 96.5%, respectively. The limits of quantitation (LOQ) were 0.1 µg/mL,
0.2 µg/mL, 0.2 µg/mL, and the limits of detection (LOD)
were 0.02, 0.03, 0.03 µg/mL for daidzein, equol and genistein, respectively.
Using the present protocol of urine analysis, no free
forms of daidzein, equol and genistein were detected. The
concentrations of the G and S of daidzein, equol and genistein were determined by HPLC through enzymolysis. Our
study found the optimal time needed for the hydrolysis with
G and S were 4 h and 2 h, respectively, in the presence of
ascorbic acid. The G and S of daidzein, equol and genistein
were detected in the urine of all volunteers. The cumulative urinary recoveries of G and S of each isoflavone over
48 h were shown in Figure 3. Most G and S of daidzein and
genistein were excreted during the first 12 hours, whereas the
majority of equol G and S were eliminated during 6 - 36 h.
The urinary excretion amount and the elimination halflives of the G and S of daidzein, equol and genistein were
shown in Table 1. The amounts of isoflavone conjugates
ranked in the order of daidzein G > daidzein S > genistein
G > equol G > equol S, genistein S. The G of daidzein and
genistein were about 2 folds of their correspondent S. The

(A)

(B)

triplicate urine standards within one day and over a period
of three days. By spiking daidzein, equol and genistein into
blank urine and water in triplicates to afford concentrations
of 2.5, 5.0 and 10.0 µg/mL, the recoveries of each isoflavone
were evaluated by comparing their concentrations obtained
from spiked urine to the corresponding ones from spiked
water. LOQ (Limit of Quantitation) represents the lowest
concentration of analyte that can be determined with acceptable precision and accuracy with coefﬁcients of variation
and relative errors below 15.0% and 20%, respectively. LOD
(Limit of Detection) represents the lowest concentration of
analyte that can be detected with S/N > 3.
VIII. Data Analysis
Owing to the presence of considerable amount of
β-glucuronidase in the sulfatase used in this study, treatment of sulfatase hydrolyzed both G and S. Accordingly,
the concentrations of S were obtained from the difference
of released aglycones between treatments with sulfatase and
glucuronidase. The amount of G and S of daidzein, equol and
genistein excreted in the specific sampling time was calculated by multiplying their concentrations by respective urine
volume collected in each time interval. The renal excretion
rates were calculated by dividing the urinary recovery over
collection time. The apparent elimination rate constants were
estimated by Sigma-Minus method in which the slope of the
regression line was obtained when the natural logarithm of
the amount not yet excreted was plotted versus time and then
transformed into half-lives.

Results
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Figure 1. Chromatograms of standards (12.5 μg/mL) in methanol (A) and soymilk sample (B).
1: daidzin (16.5 min), 2: genistin (19.5 min), 3: daidzein (22.0 min), 4: genistein (24.9 min), 5: 5,7-dimethoxycoumarin (internal standard, 27.5
min).
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Figure 2. Chromatograms of an urine sample before hydrolysis (A) and after hydrolyzed with sulfatase/glucuronidase (B).
1: daidzein (18.6 min), 2: ethylparaben (internal stardard, 14.4 min), 3: equol (26.1 min), 4: genistein (28.8 min).
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Table 1. Urinary excretion of isoflavones after intake of 800 mL
soymilk in nine volunteers

daidzein G
daidzein S
equol G
equol S
genistein G
genistein S

160
140
120

Amount excreted
(μmol)

T1/2
(h)

126.9 ± 10.2*

78.3

4.9 ± 1.1

Daidzein S

63.0 ± 10.8

38.9

5.7 ± 1.1

Equol G

28.9 ± 9.3

17.8

9.9 ± 1.8

Equol S

20.6 ± 8.5

12.7

13.3 ± 4.5

Daidzein G

100
80
60
40
20
0

% in intake
dosea

0

10

20

30

40

Time(hr)

Figure 3. Mean (±SE) cumulative urinary recoveries of glucuronides
(G) and sulfates (S) of daidzein, equol and genistein after intake of
800 mL soymilk in nine adults.

total excretion of daidzein G/S were significantly higher
than that of genistein G/S by 217.9%. The excretion amount
of equol G/S was 26.1% of daidzein G/S, and comparable
with genistein G/S. The excretion ratios of daidzein G and
daidzein S, equol G and equol S accounted for 78.3% and
38.9%, 17.8% and 12.7% of the total intake of daidzin/daidzein, whereas genistein G and genistein S were 12.8% and
6.3% of the total intake of genistin/genistein, respectively.
The mean elimination half-lives of daidzein G, daidzein S,
genistein G and genistein S were 4.9 h, 6.5 h, 5.7 h and 7.6 h,
respectively, while those of equol G and equol S were 9.9 h
and 13.3 h, respectively.

Discussion
The present study is the first work to illustrate the urine

*

Genistein G

40.1 ± 5.7

12.8

6.5 ± 1.2

Genistein S

19.5 ± 6.3

6.3

7.6 ± 1.7

Data expressed as Mean ± SE.
G: glucuronides.
S: sulfates.
* p < 0.05, compared to corresponding S.
a
800 mL of soymilk contained daidzin 96.9 µmol, daidzein 65.1
µmol, genistin 254.0 µmol and genistein 58.4 µmol. The intake
dose was based on the total amount of daidzin/daidzein or
genistin/genistein.

kinetic profiles of G and S of isoflavones after ingestion of
soymilk by adults in Taiwan. The result indicated that the
parent forms of daidzein and genistein were not present in
human urine, whereas the G and S of daidzein, equol and
genistein in urine were predominant, which echoes previous
reports(19,27).
The cumulated urinary excretion of daidzein G/S was
3-fold of genistein G/S, although the content of genistin/
genistein was 2-fold of daidzin/daidzein in the soymilk,
which was consistent with related studies(20,27,28). Contrary
to the findings in urine, previous studies have shown that the
concentrations of genistein G/S in serum were consistently
higher than those of daidzein G/S(29,30). The higher excretion
of daidzein G/S than those of genistein G/S in urine can be
accounted for by a greater fractional excretion of the latter
via bile. The difference in excretion pathway may explain
the lower recovery of genistein G/S from urine. The total
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urinary excretion of daidzein G/S and equol G/S was found
higher than the intake amount of daidzin/daidzein, which
can be explained by the presence of other ester derivatives of
daidzein in soymilk in addition to daidzin, such as malonyl
daidzin and acetyl daidzin(25).
Following ingestion of soymilk, G of daidzein and
genistein were found significantly higher than corresponding
S in urine, especially during 0 - 8 h as shown in Figure 3.
This result was in good agreement with a previous women
study, which reported that the ratios of G were 73% and
71% of the total daidzein and genistein excreted in urine(31).
Furthermore, previous studies have pointed out that G of
daidzein and genistein were the major forms in the circulation, confirming that glucuronidation and sulfation demonstrated marked selective kinetics of conjugation for daidzein
and genistein(32,33).
Equol was not a constituent in soymilk and detected
after incubation of daidzein with fecal bacteria under anoxic
condition, bringing to light that equol was a metabolite of
daidzein in gut lumen(34). Equol underwent extensive conjugation metabolism and the excretion of equol G/S lagged
behind daidzein G/S and genistein G/S. The half lives of equol
G/S were longer than those of daidzein G/S and genistein G/S.
The amount of equol S excreted in urine was comparable with
that of equol G. An in vitro cell line study has reported that
7-hydroxy group of daidzein and genistein was the main site
for glucuronidation, whereas the 4’-hydroxy group was the
only site for sulfation(35). In regard to the physical properties,
the pKa values of 7-hydroxy group of daidzein, equol and
genistein were 7.5, 9.8 and 7.8, respectively(36). The weaker
acidity of equol makes the relative lower glucuronidation of
equol than daidzein and genistein explicable.
In this study, equol G/S were detected in the urine of all
nine subjects. In contrast, previous studies have reported that
the prevalences of equol-producer in Japanese, Korean and
Chinese were 46%, 59% and 60%, respectively(24), whereas
only 14 - 34% of equol producers was reported in Caucasian(24,37). In addition, the proportion of equol producers in
postmenopausal Japanese women was 55% (six out of 11
subjects)(18). Because this study only included nine volunteers, whether the adults in Taiwan are 100% equol-producers
needs to be confirmed by future study. Asian populations
have higher proportion of equol-producer than Western
populations was suspected to be associated with habitual
diet. For instance, the equol-producers had a higher intake
of carbohydrates, phytoproteins and fiber than those of non
equol-producers(21,38,39). In addition, vegetarians had much
higher percentage of equol-producers than nonvegetarians
in Japan(40). We thus speculate that adults in Taiwan often
having high intake of soy products in their daily diets might
result in more equol-producers.
For equol-producers, besides prevention of bone loss
and fat accumulation in early postmenopausal women(41), a
reduced risk of breast cancer has been reported in premenopausal women(42). Moreover, epidemiology studies of Asian
and also some Mediterranean countries discovered that
equol-producers had lower incidence of prostate cancer(37,43).

We therefore speculate that equol G/S might contribute beneficial effects on hormone related diseases.
In conclusion, daidzein G/S and genistein G/S were the
major isoflavones  excreted in the urine of Taiwan adults after
ingestion of soymilk. Equol G/S, the metabolites of daidzein,
were produced in all nine subjects.
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